

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

#### Sheet 1 of 2

Atty Docket No.

: 9425/46702

Serial No.

: BOGOCH

Inventors Filed

: 15 May 2001

Group Art Unit

Examiner

: 1648

#### **U.S. PATENT DOCUMENTS**

Examiner Initial

Patent Number

Patent Date

Name

Class/ Filing Subclass Date

5,156,841 4,877,611

10/20/92 10/31/89 RAPP **CANTRELL**  424,88 424/88

# **FOREIGN PATENT DOCUMENTS**

Examiner Initial

Document Number

<u>Date</u>

Country

Class/

Translation

Subclass

Yes No

# OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner

Initial

1. Jean-Claude Bystryn: Tumor Vaccines; Cancer and Mestastasis Review 9:81-91, 1990

2. Freda K. Stevenson: Update on Tumor Vaccines; Int. J. Clin Lab Res 22:84:80, 1002

**EXAMINER** 

DATE CONSIDERED

Turid a Launder

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant



Sheet 2 of 2

FORM PTO-1449
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)

Atty Docket No.

: 9425/46702

Serial No.

Inventors

: BOGOCH

Filed

: 15 May 2001

Group Art Unit

: 1648

Examiner

. .

# OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial

) A) 3

Bogoch et al.: Tumor Markers: Malignin and Related Recognins Associated with Malignancy Rather Than With Cell Type; Neurochemistry and Clinical Neurology, pp. 407-424, Alan R. Liss, Inc. 1980

\_ 4.

Freda K. Stevenson: *Tumor Vaccines*, The FASEB Journal, Vol. 5, June 1991, pp. 2250-2257

5.

Jerrold H. Zar: *Biostatistical Analysis*, Prentice-Hall, Inc., Englewood Cliffs, NJ, second edition, 1984, p. 278

6.

Bogoch et al.: Elevated Levels of Anti-Malignin Antibody Are Quantitatively Related to Longer Survival in Cancer Patients; Prognosis, pp. 739-747, 1984

**EXAMINER** 

DATE CONSIDERED

David a Saunders

apy of this form with next communication to applicant